Browse Conditions Browse Medicines

Keep Me Informed - Conditions and medicines added in March 2019

The following conditions have been added to Keep Me Informed since March 1st 2019.
  • Cholecystitis
  • Liver disease
  • Vaccination
  • Polyneuropathy
  • Amyloidosis
  • Smith-Magenis syndrome
  • Autism
For information about medicines added, NICE guidelines, and patient safety information, please see the full article.

You can follow any of these conditions using Keep Me Informed, which provides users with updates about the conditions they are interested in, including updates to NICE guidelines, patient leaflets, risk management materials, information from medicine regulators and clinical trial information. To track information about these conditions please use the 'Select conditions' button.

Patient safety warnings

Warning type Conditions Medicine
Brand name
Warning
Side effect updateRheumatoid arthritis
Crohn’s disease
Ulcerative colitis
Ankylosing spondylitis
Psoriatic arthritis
Psoriasis
infliximab, brand name Remicade from Merck Sharp and DohmeSide effect of acute generalised exanthematous pustulosis (AGEP)
Side effect update Secondary hyperparathyroidism
etelcalcetide, brand name Parsabiv▼ from Amgen Seizures added as a side effect of unknown frequency
Side effect update Rheumatoid arthritis
Psoriatic arthritis
Axial spondyloarthritis
Ulcerative colitis
Juvenile idiopathic arthritis
golimumab, brand name Simponi from Merck Sharp & Dohme Lichenoid reactions added as an side effect of rare frequency.
Side effect update Rheumatoid arthritis
Juvenile idiopathic arthritis
Polyarthritis
Psoriatic arthritis
Enthesitis-related arthritis
Psoriatic arthritis
Ankylosing spondylitis
Non-radiographic axial spondyloarthritis
Plaque psoriasis
etanercept, brand name Benepali▼ from Biogen Biosimilars Lichenoid skin reactions added as an side effect of rare frequency.
Side effect update Rheumatoid arthritis
Axial spondyloarthritis
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
ertolizumab pegol, brand name Cimzia from UCB Pharma Lichenoid skin reactions added as an side effect of rare frequency.
Side effect update Chronic myeloid leukaemia (CML)
CML in ‘chronic’, ‘accelerated’ and ‘blast’ phases
Acute lymphoblastic leukaemia (ALL)
dasatinib, brand name Sprycel from UCB Pharma Thrombotic microangiopathy (TMA) is a possible adverse event of unknown frequency
Musculoskeletal pain has been reported during or after discontinuing treatment

NICE have published the following guidelines and quality standards:

Condition Ingredient/Medicine
Diffuse large B-cell lymphoma - sub-type
of non-Hodgkin lymphoma
tisagenlecleucel, brand name Kymriah▼ - from Novartis'
Hypertension in adults: diagnosis and management
-
Lung cancer: diagnosis and management
-
Lung cancer durvalumab, brand name Imfinzi▼, from AstraZeneca

The following medicines have been added to the Keep Me Informed medicines database:

Condition Ingredient Medicine Manufacturer
Constipation caused by opioid pain relief naldemedine Rizmoic▼ Shionogi
COPD formoterol and
glycopyrronium
Bevespi Aerosphere▼ AstraZeneca
Pneumonia and acute otitis media vaccine pneumococcal
polysaccharide
conjugated vaccine
Prevenar-13 Pfizer
Cystic fibrosis mannitol Bronchitol Pharmaxis Europe
Phenylketonuria (PKU) or tetrahydrobiopterin sapropterin Kuvan Biomarin
Liver disease, Thrombocytopenic disorder lusutrombopag Lusutrombopag Shionogi Shionogi
Prostate cancer apalutamide Erleada▼ Janssen-Cilag
Transthyretin amyloidosis inotersen Tegsedi Akcea Therapeutics
Rheumatoid arthritis
Juvenile idiopathic arthritis
Psoriatic arthritis
Enthesitis-related arthritis
Psoriatic arthritis
Ankylosing spondylitis
Non-radiographic axial
spondyloarthritis
Plaque psoriasis
etanercept Benepali▼ Biogen Biosimilars
Insomnia in autism
spectrum disorder (ASD)
and Smith-Magenis syndrome
melatonin Slenyto Flynn Pharmaceuticals
You can follow these medicines using our Medicines Tracker service which provides users with updates about the medicines they are interested in, including updates to Patient Leaflets, information from medicine regulators and clinical trial information. To track information about a medicine please click on the 'Select medicine' link, select the medicine you wish to follow, then select 'Follow medicine'.


Other articles
Condition Article Title Source
Cervical cancer Public Health England launches 'Cervical Screening Saves Lives' campaign Public Health England
- Update on the substitution of medicines in the event of shortages Keep Me Informed
Rare diseases Inclusion of rare disease classification Keep Me Informed
Breast cancer NHS online tool for predicting breast cancer NHS
Prostate cancer NHS publish online tool that helps men choose best prostate cancer treatment NHS
Myeloma Listening to the myeloma patient voice is difficult – but it still needs to be done Pharmaphorum

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.


Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.